Anti-Infective Agents

All Drugs and Chemicals

Posaconazole

Clotrimazole

Miconazole

Antifungal Agents

Antiprotozoal Agents

Antiparasitic Agents

Enzyme Inhibitors

Cytochrome P-450 Enzyme Inhibitors

Hormones

Hormone Antagonists

Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design

RO5503781

Daily for 5 days followed by 23 days rest per cycle

Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design

posaconazole

Clinical Trials

This multicenter, open-label study will evaluate the effect of posaconazole on the pharmacokinetics of RO5503781, the relative bioavailability of two new RO5503781 formulations, and the effect of food on the pharmacokinetics of RO5503781 in patients with solid tumors.

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

Hoffmann-La Roche

Neoplasms

Blood and Lymph Conditions

All Conditions

Leukemia

Neoplasms by Histologic Type

Hematologic Diseases

Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.

Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.

This multicenter, open label, dose-escalating study will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of RO5503781, administered once daily (QD) or once weekly (QW) in participants with advanced malignancies except leukemia. Participants will receive multiple escalating oral doses in two different dosing schedules (Sch) until disease progression or unacceptable toxicity occurs.

A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia

A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors	NCT01901172	Neoplasms	RO5503781 RO5503781 RO5503781 RO5503781 posaconazole	18 Years -	Hoffmann-La Roche
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors	NCT01901172	Neoplasms	RO5503781 RO5503781 RO5503781 RO5503781 posaconazole	18 Years -	Hoffmann-La Roche
A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia	NCT01462175	Neoplasms	RO5503781	18 Years -	Hoffmann-La Roche

Spots Global Cancer Trial Database for ro5503781

Every month we try and update this database with for ro5503781 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ro5503781

Every month we try and update this database with for ro5503781 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ro5503781 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.